I think investors need to consider the wider applications of Narmafotinib across various cancers such as ovarian, breast, lung, head, neck, prostate, melanoma etc. Just google: cancers with overly expressed FAK, and you'll get an idea of the potential market
By being somewhat successful against deadly pancreatic cancer, this gives hope to those suffering with other FAK cancers and broadens the market for Narmafotinib (FAK inhibitor) in a massive way.
Holding.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.020(7.55%) |
Mkt cap ! $95.46M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 26.0¢ | 24.0¢ | $1.992M | 7.961M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 731417 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 64376 | 1 |
View Market Depth
| Last trade - 16.19pm 25/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |